{
    "clinical_study": {
        "@rank": "136000", 
        "arm_group": {
            "arm_group_label": "RO5045337", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, extension study is designed to provide access to RO5045337 to patients who\n      have completed studies NO21279, NO21280, NP25299, NP28021 or NP28023. Patients are eligible\n      to participate in this study (NP28366) if they have shown clinical benefit on treatment of\n      RO5045337 at the completion of their respective parent study. Patients will continue on the\n      same formulation, dose and schedule of RO5045337 they were receiving at the time of\n      transitioning from the parent clinical study protocol. The anticipated time on study\n      treatment is 12 months."
        }, 
        "brief_title": "An Extension Study of RO5045337 in Patients Participating in Previous Cancer Studies", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Acute Disease", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must meet the inclusion criteria outlined in the parent protocol: NO21279,\n             NO21280, NP25299, NP28021 or NP28023\n\n          -  Patients must have completed one of the following clinical study protocols and have\n             been determined to have clinical benefit on treatment at the conclusion of required\n             study analyses as defined in the respective protocols: NO21279, NO21280, NP25299,\n             NP28021 or NP28023\n\n        Exclusion Criteria:\n\n          -  Patients must meet the exclusion criteria outlined in the parent protocol: NO21279,\n             NO21280, NP25299, NP28021 or NP28023\n\n          -  Patients who developed disease progression/ requiring other anti-tumor therapy while\n             in the parent protocol\n\n          -  Patients who have stopped study drug dosing for greater than 56 days.\n\n          -  Patients continuing to require dose modifications\n\n          -  Patients with worsening adverse events.\n\n          -  Patients with unrelated adverse events, medical illnesses, or changes in performance\n             status that, per investigator discretion, put them at high risk for continuing\n             participation in the clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677780", 
            "org_study_id": "NP28366", 
            "secondary_id": "2012-001303-20"
        }, 
        "intervention": {
            "arm_group_label": "RO5045337", 
            "description": "Patients will continue on the same formulation, dose and schedule of RO5045337 they were receiving at the time of transitioning from the parent clinical study protocol.", 
            "intervention_name": "RO5045337", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90403"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20850"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-sponsored Phase 1 Cancer Studies.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 24 months"
        }, 
        "removed_countries": {
            "country": [
                "United Kingdom", 
                "Italy"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}